| 1. |
Xu R, Barg FK, Emmett EA, et al. Association between mesothelioma and non-occupational asbestos exposure: systematic review and meta-analysis. Environ Health, 2018, 17(1): 90.
|
| 2. |
Marsh GM, Riordan AS, Keeton KA, et al. Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Occup Environ Med, 2017, 74(11): 838-846.
|
| 3. |
Bang KM, Mazurek JM, Wood JM, et al. Diseases attributable to asbestos exposure: Years of potential life lost, United States, 1999-2010. Am J Industrial Med, 2014, 57(1): 38-48.
|
| 4. |
Chang ET, Lau EC, Mowat FS, et al. Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma. Cancer Causes Control, 2017, 28(9): 971-979.
|
| 5. |
Walpole S, Pritchard AL, Cebulla CM, et al. Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide. J Natl Cancer Inst, 2018, 110(12): 1328-1341.
|
| 6. |
Pastorino S, Yoshikawa Y, Pass HI, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations [published online ahead of print, 2018 Oct 30]. J Clin Oncol, 2018, doi: 10.1200/JCO.2018.79.0352.
|
| 7. |
Betti M, Casalone E, Ferrante D, et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett, 2017, 405: 38-45.
|
| 8. |
Abdel-Rahman O. Global trends in mortality from malignant mesothelioma; analysis of WHO mortality database (1994-2013). Clin Respir J, 2018, 12(6): 2090-2100.
|
| 9. |
Taioli E, Wolf AS, Camacho-Rivera M, et al. Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14, 228 patients. PLoS One, 2015, 10(12): e0145039.
|
| 10. |
Musk AW, Olsen N, Alfonso H, et al. Predicting survival in malignant mesothelioma. Eur Respir J, 2011, 38(6): 1420-1424.
|
| 11. |
Mazurek JM, Syamlal G, Wood JM, et al. Malignant mesothelioma mortality-United States, 1999-2015. MMWR Morb Mortal Wkly Rep, 2017, 66(8): 214-218.
|
| 12. |
David S, Douglas E, Aggarwal C, et al, NCCN Thymomas and Thymic Carcinomas Panel Members. Thymomas and thymic carcinomas version 1.2020 — November 27, 2019. URL: https://www.nccn.org/professionals/physician_gls/default.aspx. Access on 2020-01.
|
| 13. |
Kim S, Bull DA, Garland L, et al. Is there a role for cancer-directed surgery in early-stage sarcomatoid or biphasic mesothelioma? Ann Thorac Surg, 2019, 107(1): 194-201.
|
| 14. |
Rice D, Rusch V, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. J Thorac Oncol, 2011, 6(8): 1304-1312.
|
| 15. |
Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, 2016, 2387(10026): 1405-1414.
|
| 16. |
Santoro A, O'Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol, 2008, 3(7): 756-763.
|
| 17. |
Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol, 2019, 20(2): 239-253.
|
| 18. |
Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med, 2019, 7(3): 260-270.
|
| 19. |
Shaikh F, Zauderer M G, Von Reibnitz D, et al. Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma. J Thorac Oncol, 2017, 12(6): 993-1000.
|
